Logo image of MITO

STEALTH BIOTHERAPEUTICS CORP (MITO) Stock Fundamental Analysis

NASDAQ:MITO - Nasdaq - US85789A1051 - ADR - Currency: USD

0.32  0 (-1.36%)

Fundamental Rating

1

Taking everything into account, MITO scores 1 out of 10 in our fundamental rating. MITO was compared to 555 industry peers in the Biotechnology industry. Both the profitability and financial health of MITO have multiple concerns. MITO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MITO has reported negative net income.
MITO Yearly Net Income VS EBIT VS OCF VS FCFMITO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -143.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MITO Yearly ROA, ROE, ROICMITO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 -1K -2K -3K

1.3 Margins

MITO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MITO Yearly Profit, Operating, Gross MarginsMITO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for MITO has been increased compared to 1 year ago.
MITO has a worse debt/assets ratio than last year.
MITO Yearly Shares OutstandingMITO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 20M 40M 60M
MITO Yearly Total Debt VS Total AssetsMITO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

MITO has a Debt/Equity ratio of -0.26. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -0.26
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
MITO Yearly LT Debt VS Equity VS FCFMITO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M -100M -150M

2.3 Liquidity

MITO has a Current Ratio of 3.68. This indicates that MITO is financially healthy and has no problem in meeting its short term obligations.
MITO has a Quick Ratio of 3.68. This indicates that MITO is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3.68
Quick Ratio 3.68
MITO Yearly Current Assets VS Current LiabilitesMITO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

MITO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.98% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.5%
EPS Next 2Y16.73%
EPS Next 3Y7.29%
EPS Next 5Y4.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MITO Yearly Revenue VS EstimatesMITO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 5M 10M 15M 20M
MITO Yearly EPS VS EstimatesMITO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MITO. In the last year negative earnings were reported.
Also next year MITO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MITO Price Earnings VS Forward Price EarningsMITO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.07
MITO Per share dataMITO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.73%
EPS Next 3Y7.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MITO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STEALTH BIOTHERAPEUTICS CORP

NASDAQ:MITO (11/15/2022, 8:00:01 PM)

0.32

0 (-1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-18 2022-11-18/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap23.54M
Analysts82.86
Price Target1.81 (465.63%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.11%
Min EPS beat(2)50.98%
Max EPS beat(2)63.24%
EPS beat(4)3
Avg EPS beat(4)29.53%
Min EPS beat(4)-47.06%
Max EPS beat(4)63.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -0.07
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.71
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -143.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity -0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.68
Altman-Z N/A
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)50.28%
Cap/Depr(5y)39.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y23.5%
EPS Next 2Y16.73%
EPS Next 3Y7.29%
EPS Next 5Y4.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16%
OCF growth 3YN/A
OCF growth 5YN/A